<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121134</url>
  </required_header>
  <id_info>
    <org_study_id>05-055</org_study_id>
    <nct_id>NCT00121134</nct_id>
  </id_info>
  <brief_title>Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer</brief_title>
  <official_title>Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harold J. Burstein, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to study the effects (good and bad) of bevacizumab
      alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or
      bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to:

        -  Examine the safety of these drugs

        -  See how easy or difficult it is to be treated with them

        -  Monitor for any signs of recurrent cancer

        -  Look at blood markers that might indicate how the treatment is working
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is broken into 4 groups (A, B, C, and D). Enrollment closed to all groups in May
      2008.

      The first forty subjects (Group A) in this study were treated with Bevacizumab only, which is
      given through a vein over 1-2 hours every 3 weeks, for a total of approximately 12 months (17
      cycles). Each cycle consists of 3 weeks.

      The next forty subjects (Group B) were treated with Bevacizumab and metronomic CM
      chemotherapy. These subjects took cyclophosphamide (1 pill by mouth every day), methotrexate,
      (1 pill taken by mouth twice a day for the first two days of each week) and Bevacizumab (once
      every 3 weeks). The treatments with cyclophosphamide, methotrexate and Bevacizumab will
      continue for approximately 6 months (8 cycles). Then for the next 6 months, they received
      Bevacizumab treatments only. The total time on this study will be about 12 months (17
      cycles).

      The next forty subjects (Group C) were treated with Bevacizumab and Capecitabine
      chemotherapy. These subjects took Capecitabine pills twice a day for 14 days, then one week
      of rest, to complete a 21-day cycle. There will be a total of 6 cycles of Capecitabine,
      meaning 18 weeks of treatment with both Capecitabine and Bevacizumab. Then received
      Bevacizumab treatments only (11 cycles) to complete 12 months of therapy. Total duration of
      your treatment will be about 12 months or 17 cycles of therapy.

      The last forty subjects (Group D) are being treated with Bevacizumab and Capecitabine
      chemotherapy on a different schedule. These subjects will take Capecitabine pills twice a day
      for 7 days, then one week of rest and repeat this for a total of 24 weeks (6 cycles). Each
      cycle will last for 4 weeks (28 days). There will be a total of 6 cycles of Capecitabine,
      meaning 24 weeks of treatment with both Capecitabine and Bevacizumab. Bevacizumab will be
      given every two weeks for a total of 24 weeks (6 cycles). Then they will receive Bevacizumab
      treatments only, every 3 weeks for additional 27 weeks (9 cycles) to complete 12 months of
      therapy. For the last 9 cycles of Bevacizumab therapy each cycle will consist of 3 weeks.
      Total duration of treatment will be about 12 months or 15 cycles of therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab with cyclophosphamide and methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine, 14 days on/7 days off scheduling, and bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 7 days on/7 days off scheduling, and bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Once a day for 6 months</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Twice daily for the first two days of every week for 6 months</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>amethopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)
Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed invasive breast cancer, preoperative stages
             II-III per AJCC 6th edition, based on baseline evaluation by clinical examination
             and/or breast imaging

          -  Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard
             chemotherapy regimen. No more chemotherapy should be planned.

          -  Patients must have completed definitive resection of primary tumor with adequate
             excision of gross disease.

          -  For patients receiving adjuvant radiation therapy, treatment must be completed prior
             to initiation of protocol therapy.

          -  Patients must have the presence of significant residual invasive disease on pathologic
             review following their preoperative chemotherapy.

          -  LVEF &gt; institutional limits of normal after preoperative chemotherapy, as assessed by
             ECHO or nuclear medicine gated study, within 30 days prior to initiating
             protocol-based treatment.

          -  ECOG performance status 0-1

        Exclusion Criteria:

          -  Inadequate organ function, as measured by laboratory assessment after preoperative
             chemotherapy and within 14 days of beginning protocol-based treatment

          -  Patients with metastatic disease are ineligible.

          -  Known HIV infection

          -  Patients may not be pregnant, expect to become pregnant, plan to conceive a child
             while on study, or breastfeeding

          -  Uncontrolled intercurrent illness

          -  Non-healing wounds or major surgical procedures (such as breast surgery) other than
             that for venous access device or diagnostic study are not permitted within 28 day
             prior to enrollment

          -  History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious,
             non-healing wound, ulcer, or bone fracture within 6 months prior to initiating
             bevacizumab

          -  Patients with any history of arterial thromboembolic events, including transient
             ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial
             infarction (MI) within the past 6 months. Patients with clinically significant
             peripheral arterial disease should also be excluded

          -  History of bleeding diathesis or coagulopathy

          -  History of grade 3 or 4 allergic reactions to compounds of similar chemical or
             biologic composition to cyclophosphamide (such as other alkylating agents) or
             methotrexate (such as other antimetabolites)

          -  Prior history of malignancy treated without curative intent, excluding nonmelanomatous
             skin cancer

          -  Patients with large or rapidly accumulating pleural or abdominal effusions

          -  Current use of anticoagulants is allowed as long as patients have been on a stable
             dose for more than two weeks with stable INR

          -  Chronic therapy with full dose aspirin (&lt; 325 mg/day) or standard non-steroidal
             anti-inflammatory agents is allowed

          -  Patients may not receive other investigational agents while on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold J Burstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>August 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 14, 2013</results_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Harold J. Burstein, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Metronomic Chemotherapy</keyword>
  <keyword>Breast Cancer Stages II-III</keyword>
  <keyword>Invasive breast cancer stages II-III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This sequential cohort phase II study was performed in the outpatient setting at four institutions between 2005 and 2008.</recruitment_details>
      <pre_assignment_details>A total of 164 participants were registered to enroll in the trial , but only 162 participants initiated treatment. So the evaluable population is 162 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A- Bevacizumab Alone</title>
          <description>Bevacizumab 15 mg/kg every 3 wks for 1 year</description>
        </group>
        <group group_id="P2">
          <title>Group B-Bevacizumab+Cyclophosphamide+Methotrexate</title>
          <description>Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for 6 months +methotrexate 2.5mg orally on day 1-2 each week for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Group C-Bevacizumab + Capcitabine(18 Wks)</title>
          <description>capecitabine 2000 mg/m2/day 14 days on/7 days off for 18 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year</description>
        </group>
        <group group_id="P4">
          <title>Group D-bevacizumab + Capecitibine (24wks)</title>
          <description>capecitabine 2000 mg orally twice per day for 7 days on/7 days off for 24 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progression of Disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Delay</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A- Bevacizumab Alone</title>
          <description>Bevacizumab 15 mg/kg every 3 wks for 1 year</description>
        </group>
        <group group_id="B2">
          <title>Group B-Bevacizumab+Cyclophosphamide+Methotrexate</title>
          <description>Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for 6 months +methotrexate 2.5mg orally on day 1-2 each week for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Group C-Bevacizumab + Capcitabine(18 Wks)</title>
          <description>capecitabine 2000 mg/m2/day 14 days on/7 days off for 18 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year</description>
        </group>
        <group group_id="B4">
          <title>Group D-bevacizumab + Capecitibine (24wks)</title>
          <description>capecitabine 2000 mg orally twice per day for 7 days on/7 days off for 24 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.05" spread="10.04"/>
                    <measurement group_id="B2" value="48.83" spread="10.34"/>
                    <measurement group_id="B3" value="48.71" spread="10.34"/>
                    <measurement group_id="B4" value="49.55" spread="9.09"/>
                    <measurement group_id="B5" value="49.03" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A- Bevacizumab Alone</title>
            <description>Bevacizumab 15 mg/kg every 3 wks for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Group B-Bevacizumab+Cyclophosphamide+Methotrexate</title>
            <description>Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for 6 months +methotrexate 2.5mg orally on day 1-2 each week for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Group C-Bevacizumab + Capcitabine(18 Wks)</title>
            <description>capecitabine 2000 mg/m2/day 14 days on/7 days off for 18 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year</description>
          </group>
          <group group_id="O4">
            <title>Group D-bevacizumab + Capecitibine (24wks)</title>
            <description>capecitabine 2000 mg orally twice per day for 7 days on/7 days off for 24 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A- Bevacizumab Alone</title>
          <description>Bevacizumab 15 mg/kg every 3 wks for 1 year</description>
        </group>
        <group group_id="E2">
          <title>Group B-Bevacizumab+Cyclophosphamide+Methotrexate</title>
          <description>Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for 6 months +methotrexate 2.5mg orally on day 1-2 each week for 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Group C-Bevacizumab + Capcitabine(18 Wks)</title>
          <description>capecitabine 2000 mg/m2/day 14 days on/7 days off for 18 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year</description>
        </group>
        <group group_id="E4">
          <title>Group D-bevacizumab + Capecitibine (24wks)</title>
          <description>capecitabine 2000 mg orally twice per day for 7 days on/7 days off for 24 weeks, and bevacizumab 15 mg/kg every 3 weeks for 1 year.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCTCAE v.3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower GI bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCTCAE v.3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="11" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="29" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="17" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hematologic-other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="108" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="51" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="58" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hemorrhage-other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="50" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E2" events="66" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E3" events="54" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E4" events="44" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="23" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="34" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="19" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="26" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="17" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" events="45" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" events="54" subjects_affected="19" subjects_at_risk="41"/>
                <counts group_id="E3" events="28" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E4" events="40" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oral cavity, hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="14" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="22" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Cardiac-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" events="23" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E4" events="39" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="9" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Tearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Vision-blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen, pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="15" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E4" events="15" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="17" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="31" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E4" events="55" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" events="31" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" events="30" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E3" events="58" subjects_affected="20" subjects_at_risk="41"/>
                <counts group_id="E4" events="32" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="17" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="30" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="37" subjects_affected="19" subjects_at_risk="41"/>
                <counts group_id="E3" events="27" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E4" events="41" subjects_affected="17" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rectum, hemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional, other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="117" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E2" events="147" subjects_affected="29" subjects_at_risk="41"/>
                <counts group_id="E3" events="149" subjects_affected="29" subjects_at_risk="41"/>
                <counts group_id="E4" events="182" subjects_affected="29" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>fever w/o neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="89" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" events="78" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" events="58" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E4" events="72" subjects_affected="18" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="19" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" events="45" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E4" events="44" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nonneuropathic generalized weakness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oral gums, pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Taste disturbance</sub_title>
                <counts group_id="E1" events="27" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="36" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E4" events="29" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Throat/Pharynx/larynx,pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Voice changes/dysarthria</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="36" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="13" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Weight Gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="42" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E4" events="9" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>creatinine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="21" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut, bronchus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, sinus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, upper airway</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, urinary tract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection w/unk ANC upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis(symptom) oral cavity</sub_title>
                <counts group_id="E1" events="29" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="43" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" events="56" subjects_affected="20" subjects_at_risk="41"/>
                <counts group_id="E4" events="36" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="22" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>bicarbonate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="10" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory-other</sub_title>
                <counts group_id="E1" events="42" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" events="67" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>back,pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="31" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" events="34" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E4" events="13" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>bone, pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>breast,pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="22" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="14" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>buttock, pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>chest wall, pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest/thoracic pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Extrapyramidal movement</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" events="43" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" events="53" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="34" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E4" events="18" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>joint, pain</sub_title>
                <counts group_id="E1" events="156" subjects_affected="31" subjects_at_risk="40"/>
                <counts group_id="E2" events="110" subjects_affected="18" subjects_at_risk="41"/>
                <counts group_id="E3" events="111" subjects_affected="23" subjects_at_risk="41"/>
                <counts group_id="E4" events="103" subjects_affected="24" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>joint-function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscle, pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="13" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="20" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="29" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="16" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neck,pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" events="121" subjects_affected="31" subjects_at_risk="40"/>
                <counts group_id="E2" events="99" subjects_affected="28" subjects_at_risk="41"/>
                <counts group_id="E3" events="106" subjects_affected="23" subjects_at_risk="41"/>
                <counts group_id="E4" events="113" subjects_affected="26" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="48" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="47" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" events="45" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E4" events="58" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="33" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="34" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E4" events="15" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="18" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="28" subjects_affected="13" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="61" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E2" events="89" subjects_affected="28" subjects_at_risk="41"/>
                <counts group_id="E3" events="77" subjects_affected="25" subjects_at_risk="41"/>
                <counts group_id="E4" events="71" subjects_affected="21" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>irregular menses</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Vagina, hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Vaginal discharge (non-infectious)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Vaginal dryness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" events="27" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" events="23" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E4" events="22" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="26" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="33" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="23" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory-other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="43" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E3" events="26" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E4" events="44" subjects_affected="16" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="11" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="10" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="170" subjects_affected="37" subjects_at_risk="41"/>
                <counts group_id="E4" events="191" subjects_affected="38" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="24" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Radiation dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title vocab="NCTCAE V3">Wound-non-infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Harold J. Burstein</name_or_title>
      <organization>DFCI</organization>
      <phone>617-632-3800</phone>
      <email>hal_burstein@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

